{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:55:03Z","timestamp":1792166103949,"version":"4.4.0"},"reference-count":234,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T00:00:00Z","timestamp":1751155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cancer remains one of the leading causes of death worldwide. New treatments like immunotherapy\u2014especially checkpoint inhibitors and CAR-T cell therapy\u2014have improved outcomes for some patients. However, these therapies often struggle to treat solid tumours effectively. Natural killer (NK) cells are part of the immune system and can naturally detect and destroy cancer cells without previous adaption. Scientists are now enhancing these cells by adding special receptors, called CARs (chimeric antigen receptors), to help them better recognize and attack cancer, an approach originally developed for T cells. CAR-NK cell therapy has some advantages over CAR-T therapy. It tends to cause fewer severe side effects, such as strong immune reactions or off-target effects in healthy tissues. Within some limitations, the allogenic use of CAR-NK cells is possible, as these cells exert less graft-versus-host activity. Such CAR-NK cell products can be produced in larger quantities and stored, making treatment more accessible. Still, there are challenges. It can be difficult to create enough modified NK cells, and the tumour microenvironment can block their activity. This review highlights recent progress in CAR-NK therapy, including early lab and clinical research. It also explores ways to improve these treatments and how they might work alongside other cancer therapies to help more patients in the future.<\/jats:p>","DOI":"10.3390\/ijms26136290","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T06:56:54Z","timestamp":1751353014000},"page":"6290","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Rendering NK Cells Antigen-Specific for the Therapy of Solid Tumours"],"prefix":"10.3390","volume":"26","author":[{"given":"Carina A.","family":"Doeppner","sequence":"first","affiliation":[{"name":"Department of Dermatology, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany"},{"name":"Deutsches Zentrum Immuntherapie (DZI), 91054 Erlangen, Germany"},{"name":"Bavarian Cancer Research Center (BZKF), 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center W\u00fcrzburg Erlangen Regensburg Augsburg (CCC-WERA), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7338-8503","authenticated-orcid":false,"given":"Amanda Katharina","family":"Binder","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany"},{"name":"Deutsches Zentrum Immuntherapie (DZI), 91054 Erlangen, Germany"},{"name":"Bavarian Cancer Research Center (BZKF), 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center W\u00fcrzburg Erlangen Regensburg Augsburg (CCC-WERA), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6119-2542","authenticated-orcid":false,"given":"Franziska","family":"Bremm","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany"},{"name":"Deutsches Zentrum Immuntherapie (DZI), 91054 Erlangen, Germany"},{"name":"Bavarian Cancer Research Center (BZKF), 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center W\u00fcrzburg Erlangen Regensburg Augsburg (CCC-WERA), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Feuchter","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany"},{"name":"Deutsches Zentrum Immuntherapie (DZI), 91054 Erlangen, Germany"},{"name":"Bavarian Cancer Research Center (BZKF), 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center W\u00fcrzburg Erlangen Regensburg Augsburg (CCC-WERA), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3478-0741","authenticated-orcid":false,"given":"Jan","family":"D\u00f6rrie","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany"},{"name":"Deutsches Zentrum Immuntherapie (DZI), 91054 Erlangen, Germany"},{"name":"Bavarian Cancer Research Center (BZKF), 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center W\u00fcrzburg Erlangen Regensburg Augsburg (CCC-WERA), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8236-9298","authenticated-orcid":false,"given":"Niels","family":"Schaft","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany"},{"name":"Deutsches Zentrum Immuntherapie (DZI), 91054 Erlangen, Germany"},{"name":"Bavarian Cancer Research Center (BZKF), 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center W\u00fcrzburg Erlangen Regensburg Augsburg (CCC-WERA), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000365632","article-title":"Human natural killer cells: Origin, receptors, function, and clinical applications","volume":"164","author":"Moretta","year":"2014","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.coi.2018.02.004","article-title":"NKG2D and its ligands in cancer","volume":"51","author":"Dhar","year":"2018","journal-title":"Curr. Opin. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-01014-w","article-title":"NK cell-based cancer immunotherapy: From basic biology to clinical development","volume":"14","author":"Liu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.canlet.2021.07.032","article-title":"Natural killer cells in cancer and cancer immunotherapy","volume":"520","author":"Raskov","year":"2021","journal-title":"cancer letters"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.immuni.2017.10.008","article-title":"The broad spectrum of human natural killer cell diversity","volume":"47","author":"Freud","year":"2017","journal-title":"Immunity"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Barrow, A.D., Martin, C.J., and Colonna, M. (2019). The natural cytotoxicity receptors in health and disease. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00909"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nri2604","article-title":"Oncogenic stress sensed by the immune system: Role of natural killer cell receptors","volume":"9","author":"Raulet","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nri3365","article-title":"Innate lymphoid cells\u2014A proposal for uniform nomenclature","volume":"13","author":"Spits","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1365-2141.2009.07667.x","article-title":"Replicative potential of human natural killer cells","volume":"145","author":"Fujisaki","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/s41590-024-01883-0","article-title":"High-dimensional single-cell analysis of human natural killer cell heterogeneity","volume":"25","author":"Rebuffet","year":"2024","journal-title":"Nat. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1158\/2326-6066.CIR-18-0500","article-title":"A gene signature predicting natural killer cell infiltration and improved survival in melanoma patients","volume":"7","author":"Cursons","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.2174\/1389450121666200910160929","article-title":"The activating receptors of natural killer cells and their inter-switching potentials","volume":"21","author":"Rowaiye","year":"2020","journal-title":"Curr. Drug Targets"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev.immunol.19.1.197","article-title":"Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis","volume":"19","author":"Moretta","year":"2001","journal-title":"Annu. Rev. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1084\/jem.187.12.2065","article-title":"NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non\u2013major histocompatibility complex\u2013restricted tumor cell lysis","volume":"187","author":"Vitale","year":"1998","journal-title":"J. Exp. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1084\/jem.188.5.953","article-title":"Molecular cloning of NKp46: A novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity","volume":"188","author":"Pessino","year":"1998","journal-title":"J. Exp. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1084\/jem.20090681","article-title":"The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans","volume":"206","author":"Brandt","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1084\/jem.186.7.1129","article-title":"p46, a novel natural killer cell\u2013specific surface molecule that mediates cell activation","volume":"186","author":"Sivori","year":"1997","journal-title":"J. Exp. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1158\/2326-6066.CIR-18-0733","article-title":"CD28 homolog is a strong activator of natural killer cells for lysis of B7H7+ tumor cells","volume":"7","author":"Zhuang","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41420-024-01815-9","article-title":"Breakthrough of solid tumor treatment: CAR-NK immunotherapy","volume":"10","author":"Wang","year":"2024","journal-title":"Cell Death Discov."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/nature03884","article-title":"The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor","volume":"436","author":"Gasser","year":"2005","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1126\/science.279.5357.1737","article-title":"Recognition of stress-induced MHC molecules by intestinal epithelial \u03b3\u03b4 T cells","volume":"279","author":"Groh","year":"1998","journal-title":"Science"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/85321","article-title":"Costimulation of CD8\u03b1\u03b2 T cells by NKG2D via engagement by MIC induced on virus-infected cells","volume":"2","author":"Groh","year":"2001","journal-title":"Nat. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2147\/ITT.S306109","article-title":"Key activating and inhibitory ligands involved in the mobilization of natural killer cells for cancer immunotherapies","volume":"ume 10","author":"Karmakar","year":"2021","journal-title":"ImmunoTargets Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41568-020-0272-z","article-title":"The cancer\u2013natural killer cell immunity cycle","volume":"20","author":"Huntington","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Buckle, I., and Guillerey, C. (2021). Inhibitory receptors and immune checkpoints regulating natural killer cell responses to cancer. Cancers, 13.","DOI":"10.3390\/cancers13174263"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1084\/jem.171.3.695","article-title":"A novel surface antigen expressed by a subset of human CD3-CD16+ natural killer cells. Role in cell activation and regulation of cytolytic function","volume":"171","author":"Moretta","year":"1990","journal-title":"J. Exp. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1600-065X.1997.tb00946.x","article-title":"Killer cell inhibitory receptors: Diversity, specificity, and function","volume":"155","author":"Long","year":"1997","journal-title":"Immunol. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1126\/science.1103478","article-title":"Natural killer cell signaling pathways","volume":"306","author":"Vivier","year":"2004","journal-title":"Science"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nature03847","article-title":"Licensing of natural killer cells by host major histocompatibility complex class I molecules","volume":"436","author":"Kim","year":"2005","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/319675a0","article-title":"Selective rejection of H\u20132-deficient lymphoma variants suggests alternative immune defence strategy","volume":"319","author":"Ljunggren","year":"1986","journal-title":"Nature"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Sivori, S., Della Chiesa, M., Carlomagno, S., Quatrini, L., Munari, E., Vacca, P., Tumino, N., Mariotti, F.R., Mingari, M.C., and Pende, D. (2020). Inhibitory receptors and checkpoints in human NK cells, implications for the immunotherapy of cancer. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.02156"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"106932","DOI":"10.1016\/j.imlet.2024.106932","article-title":"NK cell receptors in anti-tumor and healthy tissue protection: Mechanisms and therapeutic advances","volume":"270","author":"Greppi","year":"2024","journal-title":"Immunol. Lett."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Paul, S., and Lal, G. (2017). The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.01124"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.4049\/jimmunol.167.4.2068","article-title":"A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells","volume":"167","author":"Screpanti","year":"2001","journal-title":"J. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/JLB.MR0718-269R","article-title":"Mechanisms of natural killer cell-mediated cellular cytotoxicity","volume":"105","author":"Prager","year":"2019","journal-title":"J. Leukoc. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Wang, W., Erbe, A.K., Hank, J.A., Morris, Z.S., and Sondel, P.M. (2015). NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Front. Immunol., 6.","DOI":"10.3389\/fimmu.2015.00368"},{"key":"ref_37","first-page":"1","article-title":"Solid tumors: Facts, challenges and solutions","volume":"2","author":"Gavhane","year":"2011","journal-title":"Int J Pharm Sci Res"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1158\/1078-0432.CCR-17-3509","article-title":"A pan-cancer landscape of interactions between solid tumors and infiltrating immune cell populations","volume":"24","author":"Tamborero","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.4049\/jimmunol.1202693","article-title":"Neuroblastoma-derived TGF-\u03b21 modulates the chemokine receptor repertoire of human resting NK cells","volume":"190","author":"Castriconi","year":"2013","journal-title":"J. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1053\/j.gastro.2021.04.064","article-title":"TGF-\u03b2 signaling in liver, pancreas, and gastrointestinal diseases and cancer","volume":"161","author":"Gough","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41467-017-00396-9","article-title":"SIRT7 antagonizes TGF-\u03b2 signaling and inhibits breast cancer metastasis","volume":"8","author":"Tang","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Caja, L., Dituri, F., Mancarella, S., Caballero-Diaz, D., Moustakas, A., Giannelli, G., and Fabregat, I. (2018). TGF-\u03b2 and the Tissue Microenvironment: Relevance in Fibrosis and Cancer. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19051294"},{"key":"ref_44","first-page":"405","article-title":"Tumor interstitial fluid as modulator of cancer inflammation, thrombosis, immunity and angiogenesis","volume":"32","author":"Baronzio","year":"2012","journal-title":"Anticancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1158\/2159-8290.CD-13-0985","article-title":"T-cell and NK-cell infiltration into solid tumors: A key limiting factor for efficacious cancer immunotherapy","volume":"4","author":"Melero","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1365-2567.2007.02573.x","article-title":"In vivo kinetics of human natural killer cells: The effects of ageing and acute and chronic viral infection","volume":"121","author":"Zhang","year":"2007","journal-title":"Immunology"},{"key":"ref_48","first-page":"5758","article-title":"Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells","volume":"119","author":"Gill","year":"2012","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"122381","DOI":"10.1016\/j.lfs.2023.122381","article-title":"Current progress of chimeric antigen receptor (CAR) T versus CAR NK cell for immunotherapy of solid tumors","volume":"337","author":"Esmaeilzadeh","year":"2024","journal-title":"Life Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: Current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Andrea, A.E., Chiron, A., Sarrabayrouse, G., Bessoles, S., and Hacein-Bey-Abina, S. (2024). A structural, genetic and clinical comparison of CAR-T cells and CAR-NK cells: Companions or competitors?. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1459818"},{"key":"ref_53","first-page":"1177","article-title":"Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy","volume":"139","author":"Cashen","year":"2022","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Schmidt, P., Raftery, M.J., and Pecher, G. (2021). Engineering NK cells for CAR therapy\u2014Recent advances in gene transfer methodology. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.611163"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/jleuko\/qiad074","article-title":"Nonviral technologies can pave the way for CAR-NK cell therapy","volume":"114","author":"Bexte","year":"2023","journal-title":"J. Leukoc. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Hinnekens, C., De Smedt, S.C., Fraire, J.C., and Braeckmans, K. (2023). Non-viral engineering of NK cells. Biotechnol. Adv., 68.","DOI":"10.1016\/j.biotechadv.2023.108212"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41419-024-06438-7","article-title":"Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: From bench to bedside","volume":"15","author":"Zhang","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Veluchamy, J.P., Kok, N., van der Vliet, H.J., Verheul, H.M., de Gruijl, T.D., and Spanholtz, J. (2017). The rise of allogeneic natural killer cells as a platform for cancer immunotherapy: Recent innovations and future developments. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.00631"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e002128","DOI":"10.1136\/jitc-2020-002128","article-title":"Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells","volume":"9","author":"Lee","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","article-title":"The biology of human natural killer-cell subsets","volume":"22","author":"Cooper","year":"2001","journal-title":"Trends Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1146\/annurev.immunol.17.1.19","article-title":"The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens","volume":"17","author":"Waldmann","year":"1999","journal-title":"Annu. Rev. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4887","DOI":"10.1182\/blood-2002-11-3392","article-title":"IL-15 is an essential mediator of peripheral NK-cell homeostasis","volume":"101","author":"Ranson","year":"2003","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"A59","DOI":"10.1158\/2326-6074.TUMIMM17-A59","article-title":"Abstract A59: Expression of membrane-bound IL-15\/IL-15R\u03b1 complex in chimeric antigen receptor-engineered natural killer cells for enhanced efficacy against solid tumors","volume":"6","author":"Siegler","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s00262-012-1212-x","article-title":"Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor","volume":"61","author":"Sahm","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Silvestre, R.N., Eitler, J., de Azevedo, J.T.C., Tirapelle, M.C., Fantacini, D.M.C., de Souza, L.E.B., Swiech, K., Covas, D.T., Calado, R.T., and Montero, P.O. (2023). Engineering NK-CAR. 19 cells with the IL-15\/IL-15R\u03b1 complex improved proliferation and anti-tumor effect in vivo. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1226518"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13045-024-01525-w","article-title":"IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts","volume":"17","author":"Gehrcken","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1053\/j.gastro.2021.12.281","article-title":"Off-the-shelf prostate stem cell antigen\u2013directed chimeric antigen receptor natural killer cell therapy to treat pancreatic cancer","volume":"162","author":"Teng","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"6824","DOI":"10.1182\/blood-2023-178289","article-title":"CD19-specific CAR NK cells coexpressing IL-21 exhibit superior expansion and antitumor activity against CD19-postive lymphoma","volume":"142","author":"He","year":"2023","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Zhang, C., He, M., Xing, W., Hou, R., and Zhang, H. (2024). Co-expression of IL-21-Enhanced NKG2D CAR-NK cell therapy for lung cancer. BMC Cancer, 24.","DOI":"10.1186\/s12885-023-11806-1"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nri.2015.9","article-title":"Natural killer cell memory in infection, inflammation and cancer","volume":"16","author":"Cerwenka","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/nri.2016.13","article-title":"Immunological memory: Lessons from the past and a look to the future","volume":"16","author":"Farber","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e2122379119","DOI":"10.1073\/pnas.2122379119","article-title":"Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia","volume":"119","author":"Dong","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"234","DOI":"10.54254\/2753-8818\/20\/20230777","article-title":"Synergizing CAR with memory-like NK cells","volume":"20","author":"Wang","year":"2023","journal-title":"Theor. Nat. Sci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cytogfr.2020.12.003","article-title":"Chemokine networks modulating natural killer cell trafficking to solid tumors","volume":"59","author":"Yao","year":"2021","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"200777","DOI":"10.1016\/j.omton.2024.200777","article-title":"Empowering pancreatic tumor homing with augmented anti-tumor potency of CXCR2-tethered CAR-NK cells","volume":"32","author":"Yoon","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1189\/jlb.71.2.173","article-title":"Role of chemokines in the biology of natural killer cells","volume":"71","author":"Robertson","year":"2002","journal-title":"J. Leukoc. Biol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.omto.2019.12.006","article-title":"CXCR1 expression to improve anti-cancer efficacy of intravenously injected CAR-NK cells in mice with peritoneal xenografts","volume":"16","author":"Ng","year":"2020","journal-title":"Mol. Ther.-Oncolytics"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Franz\u00e9n, A.S., Boulifa, A., Radecke, C., Stintzing, S., Raftery, M.J., and Pecher, G. (2024). Next-generation CEA-CAR-NK-92 cells against solid tumors: Overcoming Tumor Microenvironment challenges in Colorectal Cancer. Cancers, 16.","DOI":"10.3390\/cancers16020388"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2303963","DOI":"10.1002\/adhm.202303963","article-title":"Mnox Nanoenzyme Armed CAR-NK Cells Enhance Solid Tumor Immunotherapy by Alleviating the Immunosuppressive Microenvironment","volume":"13","author":"Duan","year":"2024","journal-title":"Adv. Healthc. Mater."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/2326-6066.CIR-21-0435","article-title":"C3aR signaling inhibits NK-cell infiltration into the tumor microenvironment in mouse models","volume":"10","author":"Nandagopal","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e27196","DOI":"10.1016\/j.heliyon.2024.e27196","article-title":"CAR-NK cells in combination therapy against cancer: A potential paradigm","volume":"10","author":"Li","year":"2024","journal-title":"Heliyon"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"ref_84","first-page":"669","article-title":"Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity","volume":"2","author":"Meropol","year":"1996","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1084\/jem.180.4.1395","article-title":"Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor","volume":"180","author":"Carson","year":"1994","journal-title":"J. Exp. Med."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Ojo, E.O., Sharma, A.A., Liu, R., Moreton, S., Checkley-Luttge, M.-A., Gupta, K., Lee, G., Lee, D.A., Otegbeye, F., and Sekaly, R.-P. (2019). Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-51287-6"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Senju, H., Kumagai, A., Nakamura, Y., Yamaguchi, H., Nakatomi, K., Fukami, S., Shiraishi, K., Harada, Y., Nakamura, M., and Okamura, H. (2018). Effect of IL-18 on the expansion and phenotype of human natural killer cells: Application to cancer immunotherapy. Int. J. Biol. Sci., 14.","DOI":"10.7150\/ijbs.22809"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/CJI.0000000000000483","article-title":"Mesothelin-targeted CAR-NK cells derived from induced pluripotent stem cells have a high efficacy in killing triple-negative breast cancer cells as shown in several preclinical models","volume":"46","author":"Yang","year":"2023","journal-title":"J. Immunother."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1158\/2326-6066.CIR-23-1017","article-title":"Engineered CAR-NK cells with tolerance to H2O2 and hypoxia can suppress postoperative relapse of triple-negative breast cancers","volume":"12","author":"Liu","year":"2024","journal-title":"Cancer Immunol. Res."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Raftery, M.J., Franz\u00e9n, A.S., Radecke, C., Boulifa, A., Sch\u00f6nrich, G., Stintzing, S., Blohmer, J.-U., and Pecher, G. (2023). Next generation CD44v6-specific CAR-NK cells effective against triple negative breast cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24109038"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Hu, Z. (2020). Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-59736-3"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e12858","DOI":"10.1111\/cpr.12858","article-title":"Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor","volume":"53","author":"Liu","year":"2020","journal-title":"Cell Prolif."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"27764","DOI":"10.18632\/oncotarget.8526","article-title":"A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/neuonc\/noad087","article-title":"Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma","volume":"25","author":"Burger","year":"2023","journal-title":"Neuro-Oncology"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"djv375","DOI":"10.1093\/jnci\/djv375","article-title":"ErbB2\/HER2-specific NK cells for targeted therapy of glioblastoma","volume":"108","author":"Zhang","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2127508","DOI":"10.1080\/2162402X.2022.2127508","article-title":"AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma","volume":"11","author":"Strecker","year":"2022","journal-title":"Oncoimmunology"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Han, J., Chu, J., Keung Chan, W., Zhang, J., Wang, Y., Cohen, J.B., Victor, A., Meisen, W.H., Kim, S.-h., and Grandi, P. (2015). CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells. Sci. Rep., 5.","DOI":"10.1038\/srep11483"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/CJI.0000000000000082","article-title":"Engineering NK cells modified with an EGFRvIII-specific chimeric antigen receptor to overexpress CXCR4 improves immunotherapy of CXCL12\/SDF-1\u03b1-secreting glioblastoma","volume":"38","author":"Michen","year":"2015","journal-title":"J. Immunother."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1158\/0008-5472.CAN-21-0035","article-title":"An oncolytic virus expressing IL15\/IL15R\u03b1 combined with off-the-shelf EGFR-CAR NK cells targets glioblastoma","volume":"81","author":"Ma","year":"2021","journal-title":"Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s00262-024-03808-0","article-title":"Antitumor effects of intracranial injection of B7-H3-targeted Car-T and Car-Nk cells in a patient-derived glioblastoma xenograft model","volume":"73","author":"Tachi","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Yang, S., Cao, B., Zhou, G., Zhu, L., Wang, L., Zhang, L., Kwok, H.F., Zhang, Z., and Zhao, Q. (2020). Targeting B7-H3 immune checkpoint with chimeric antigen receptor-engineered natural killer cells exhibits potent cytotoxicity against non-small cell lung cancer. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.01089"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.omtm.2022.10.010","article-title":"Co-transducing B7H3 CAR-NK cells with the DNR preserves their cytolytic function against GBM in the presence of exogenous TGF-\u03b2","volume":"27","author":"Chaudhry","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Nath, P.R., Alam, S., Vu, B., Bonan, N., Marin, N., Dey, S., and Dash, P. (2024). 300 Development of CAR-NK cells for the treatment of human glioblastoma multiforme. BMJ Spec. J.","DOI":"10.1136\/jitc-2024-SITC2024.0300"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"B034","DOI":"10.1158\/2326-6074.TUMIMM24-B034","article-title":"Abstract B034: Assessing the cytotoxic potential of novel CAR-NK cells targeting glioblastoma stem cell antigens","volume":"12","author":"Lima","year":"2024","journal-title":"Cancer Immunol. Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.molimm.2020.04.016","article-title":"A novel chimeric PD1-NKG2D-41BB receptor enhances antitumor activity of NK92 cells against human lung cancer H1299 cells by triggering pyroptosis","volume":"122","author":"Lu","year":"2020","journal-title":"Mol. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/JLB.5MA0122-467R","article-title":"CAR NK-92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivo","volume":"112","author":"Liu","year":"2022","journal-title":"J. Leukoc. Biol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"6360","DOI":"10.1158\/1538-7445.AM2024-6360","article-title":"A novel CAR-NK cell therapy to target lung adenocarcinoma cells","volume":"84","author":"Zolov","year":"2024","journal-title":"Cancer Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e73699","DOI":"10.7554\/eLife.73699","article-title":"Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors","volume":"11","author":"Chambers","year":"2022","journal-title":"Elife"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2054105","DOI":"10.1080\/2162402X.2022.2054105","article-title":"STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer","volume":"11","author":"Da","year":"2022","journal-title":"Oncoimmunology"},{"key":"ref_110","first-page":"2823","article-title":"Development of c-MET-specific chimeric antigen receptor-engineered natural killer cells with cytotoxic effects on human liver cancer HepG2 cells","volume":"20","author":"Liu","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Cao, B., Ni, Q., Chen, Z., Yang, S., Zhang, X., Su, H., Zhang, Z., Zhao, Q., Zhu, X., and Liu, M. (2025). Development of glypican-3-specific chimeric antigen receptor-modified natural killer cells and optimization as a therapy for hepatocellular carcinoma. J. Leukoc. Biol., 117.","DOI":"10.1093\/jleuko\/qiae144"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Yang, L., Pham, K., Xi, Y., Wu, Q., Liu, D., Robertson, K.D., and Liu, C. (2025). Exploring Glypican-3 targeted CAR-NK treatment and potential therapy resistance in hepatocellular carcinoma. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0317401"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Cao, B., Liu, M., Huang, J., Zhou, J., Li, J., Lian, H., Huang, W., Guo, Y., Yang, S., and Lin, L. (2021). Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer. Int. J. Biol. Sci., 17.","DOI":"10.7150\/ijbs.64630"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"107637","DOI":"10.1016\/j.phrs.2025.107637","article-title":"Chimeric Cytokine Receptor TGF-\u03b2 R\u2161\/IL-21R Improves CAR-NK Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Gastric Cancer","volume":"212","author":"Ren","year":"2025","journal-title":"Pharmacol. Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.ymthe.2019.03.011","article-title":"Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients","volume":"27","author":"Xiao","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12865-018-0262-z","article-title":"Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells","volume":"19","author":"Shiozawa","year":"2018","journal-title":"BMC Immunol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"4263520","DOI":"10.1155\/2018\/4263520","article-title":"Combination therapy with EpCAM-CAR-NK-92 cells and regorafenib against human colorectal cancer models","volume":"2018","author":"Zhang","year":"2018","journal-title":"J. Immunol. Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"6915912","DOI":"10.1155\/2017\/6915912","article-title":"Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma","volume":"2017","author":"Zhang","year":"2017","journal-title":"J. Immunol. Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2340186","DOI":"10.2144\/fsoa-2023-0135","article-title":"Promising approach for targeting ROBO1 with CAR NK cells to combat ovarian cancer primary tumor cells and organoids","volume":"10","author":"Zhu","year":"2024","journal-title":"Future Sci. OA"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Li, J., Hu, H., Lian, H., Yang, S., Liu, M., He, J., Cao, B., Chen, D., Hu, Y., and Zhi, C. (2024). NK-92MI cells engineered with anti-claudin-6 chimeric antigen receptors in immunotherapy for ovarian cancer. Int. J. Biol. Sci., 20.","DOI":"10.7150\/ijbs.88539"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e13727","DOI":"10.1111\/cpr.13727","article-title":"Mesothelin CAR-engineered NK cells derived from human embryonic stem cells suppress the progression of human ovarian cancer in animals","volume":"57","author":"Liu","year":"2024","journal-title":"Cell Prolif."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s40164-022-00341-7","article-title":"Chimeric antigen receptor-engineered NK cells: New weapons of cancer immunotherapy with great potential","volume":"11","author":"Wang","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"S851","DOI":"10.1016\/j.annonc.2021.08.1390","article-title":"1006P ACE1702, a first-in-class, off-the-shelf, selected natural killer cell [oNK] product using antibody cell conjugation technology [ACC], with pre-clinical and early clinical activity in HER2< 3+ tumors","volume":"32","author":"Mahalingam","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"09636897221094244","DOI":"10.1177\/09636897221094244","article-title":"Cytokine release syndrome after modified CAR-NK therapy in an advanced non-small cell lung cancer patient: A case report","volume":"31","author":"Zhang","year":"2022","journal-title":"Cell Transplant."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Chocarro, L., Bocanegra, A., Blanco, E., Fern\u00e1ndez-Rubio, L., Arasanz, H., Echaide, M., Garnica, M., Ramos, P., Pi\u00f1eiro-Hermida, S., and Vera, R. (2022). Cutting-Edge: Preclinical and clinical development of the first approved Lag-3 inhibitor. Cells, 11.","DOI":"10.3390\/cells11152351"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e901","DOI":"10.1002\/ctm2.901","article-title":"Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer","volume":"12","author":"Wang","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"eadd1187","DOI":"10.1126\/sciadv.add1187","article-title":"Successful targeting of PD-1\/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model","volume":"8","author":"Liu","year":"2022","journal-title":"Sci. Adv."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Klapdor, R., Wang, S., Morgan, M.A., Zimmermann, K., Hachenberg, J., B\u00fcning, H., D\u00f6rk, T., Hillemanns, P., and Schambach, A. (2021). NK cell-mediated eradication of ovarian cancer cells with a novel chimeric antigen receptor directed against CD44. Biomedicines, 9.","DOI":"10.3390\/biomedicines9101339"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1089\/hum.2017.168","article-title":"Improved killing of ovarian cancer stem cells by combining a novel chimeric antigen receptor\u2013based immunotherapy and chemotherapy","volume":"28","author":"Klapdor","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.21873\/anticanres.13796","article-title":"Robo1-specific CAR-NK immunotherapy enhances efficacy of 125I seed brachytherapy in an orthotopic mouse model of human pancreatic carcinoma","volume":"39","author":"Xia","year":"2019","journal-title":"Anticancer Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1186\/s12967-024-05724-4","article-title":"Radiotherapy enhances the anti-tumor effect of CAR-NK cells for hepatocellular carcinoma","volume":"22","author":"Lin","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1158\/2326-6066.CIR-22-0017","article-title":"Activation of tumor-cell STING primes NK-cell therapy","volume":"10","author":"Knelson","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"ref_133","first-page":"3714","article-title":"Bortezomib improves adoptive carbonic anhydrase IX-specific chimeric antigen receptor-modified NK92 cell therapy in mouse models of human renal cell carcinoma","volume":"40","author":"Zhang","year":"2018","journal-title":"Oncol. Rep."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"200927","DOI":"10.1016\/j.omton.2024.200927","article-title":"Combinatorial immunotherapy with anti-ROR1 CAR NK cells and an IL-21 secreting oncolytic virus against neuroblastoma","volume":"33","author":"Chu","year":"2025","journal-title":"Mol. Ther. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2101397","DOI":"10.1002\/smll.202101397","article-title":"Temperature-feedback nanoplatform for NIR-II penta-modal imaging-guided synergistic photothermal therapy and CAR-NK immunotherapy of lung cancer","volume":"17","author":"Xu","year":"2021","journal-title":"Small"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/cmi.2014.91","article-title":"NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma","volume":"12","author":"Sun","year":"2015","journal-title":"Cell. Mol. Immunol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"ref_139","first-page":"4415","article-title":"CAR-T 19 combined with reduced-dose PD-1 blockade therapy for treatment of refractory follicular lymphoma: A case report","volume":"18","author":"Wang","year":"2019","journal-title":"Oncol Lett"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"108382","DOI":"10.1016\/j.clim.2020.108382","article-title":"Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies","volume":"214","author":"Song","year":"2020","journal-title":"Clin. Immunol."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Pesce, S., Greppi, M., Grossi, F., Del Zotto, G., Moretta, L., Sivori, S., Genova, C., and Marcenaro, E. (2019). PD\/1-PD-Ls checkpoint: Insight on the potential role of NK cells. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01242"},{"key":"ref_142","first-page":"2286","article-title":"The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: A therapeutic target for CT-011, a novel monoclonal anti\u2013PD-1 antibody","volume":"116","author":"Bakan","year":"2010","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Della Chiesa, M., Pesce, S., Muccio, L., Carlomagno, S., Sivori, S., Moretta, A., and Marcenaro, E. (2016). Features of memory-like and PD-1+ human NK cell subsets. Front. Immunol., 7.","DOI":"10.3389\/fimmu.2016.00351"},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Abdolahi, S., Ghazvinian, Z., Muhammadnejad, S., Ahmadvand, M., Aghdaei, H.A., Ebrahimi-Barough, S., Ai, J., Zali, M.R., Verdi, J., and Baghaei, K. (2021). Adaptive NK cell therapy modulated by anti-PD-1 antibody in gastric cancer model. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.733075"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1172\/JCI99317","article-title":"Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade","volume":"128","author":"Hsu","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jaci.2016.04.025","article-title":"Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization","volume":"139","author":"Pesce","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jcyt.2016.10.009","article-title":"Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma","volume":"19","author":"Oelsner","year":"2017","journal-title":"Cytotherapy"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"e000450","DOI":"10.1136\/jitc-2019-000450","article-title":"PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations","volume":"8","author":"Fabian","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"ii15","DOI":"10.1093\/neuonc\/noab180.049","article-title":"OS12. 6. A combination therapy of CAR-NK-cells and anti-PD-1 results in high efficacy against advanced-stage glioblastoma in a syngeneic mouse model and induces protective anti-tumor immunity in vivo","volume":"23","author":"Strassheimer","year":"2021","journal-title":"Neuro-Oncology"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cei.13592","article-title":"Immune checkpoint inhibitors and cellular treatment for lymphoma immunotherapy","volume":"205","author":"Li","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Chen, X., Xue, L., Ding, X., Zhang, J., Jiang, L., Liu, S., Hou, H., Jiang, B., Cheng, L., and Zhu, Q. (2022). An Fc-competent anti-human TIGIT blocking antibody ociperlimab (BGB-A1217) elicits strong immune responses and potent anti-tumor efficacy in pre-clinical models. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.828319"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity","volume":"19","author":"Zhang","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Berclaz, L.M., Altendorf-Hofmann, A., Lindner, L.H., Burkhard-Meier, A., Di Gioia, D., D\u00fcrr, H.R., Klein, A., Albertsmeier, M., Schmidt-Hegemann, N.-S., and Klauschen, F. (2023). TIM-3 Qualifies as a Potential Immunotherapeutic Target in Specific Subsets of Patients with High-Risk Soft Tissue Sarcomas (HR-STS). Cancers, 15.","DOI":"10.3390\/cancers15102735"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1016\/j.ymthe.2017.08.010","article-title":"Combination cancer therapy using chimeric antigen receptor-engineered natural killer cells as drug carriers","volume":"25","author":"Siegler","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_155","unstructured":"Wang, P., Siegler, E., Chen, X., and Kim, Y.J. (2020). Combination Cancer Therapy Using Chimeric Antigen Receptor Engineered Natural Killer Cells as Chemotherapeutic Drug Carriers. (Application No. 2020US20200197533A1), U.S. Patent."},{"key":"ref_156","first-page":"524","article-title":"Navigating chimeric antigen receptor-engineered natural killer cells as drug carriersviathree-dimensional mapping of the tumor microenvironment","volume":"362","author":"Huang","year":"2023","journal-title":"J. Ophthalmol. Clin. Res."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"He, J., Yan, Y., Zhang, J., Wei, Z., Li, H., and Xing, L. (2023). Synergistic treatment strategy: Combining CAR-NK cell therapy and radiotherapy to combat solid tumors. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1298683"},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Yan, X., Yao, C., Fang, C., Han, M., Gong, C., Hu, D., Shen, W., Wang, L., Li, S., and Zhu, S. (2022). Rocaglamide promotes the infiltration and antitumor immunity of NK cells by activating cGAS-STING signaling in non-small cell lung cancer. Int. J. Biol. Sci., 18.","DOI":"10.7150\/ijbs.65019"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0721-x","article-title":"Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy","volume":"12","author":"Li","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00977-0","article-title":"Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001\u20132020)","volume":"13","author":"Huang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_161","first-page":"66","article-title":"Tyrosine kinase blockers: New hope for successful cancer therapy","volume":"9","author":"Pytel","year":"2009","journal-title":"Anti-Cancer Agents Med. Chem. (Former. Curr. Med. Chem.-Anti-Cancer Agents)"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ejca.2010.11.021","article-title":"Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma","volume":"47","author":"Busse","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"S517","DOI":"10.1016\/j.htct.2023.09.953","article-title":"Anti-cd19 cars armed with nk receptor-derived activation domains demonstrate to improve car-nk antitumor effector function and are differentially enhanced by dasatinib","volume":"45","author":"Santos","year":"2023","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.18001\/TRS.7.5.104","article-title":"Combination Therapy with EGFR Specific CAR_NK_92 Cells and Cabozantinib against Human Renal Cell Carcinoma","volume":"7","author":"Huang","year":"2021","journal-title":"Tob. Regul. Sci. (TRS)"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4049\/jimmunol.180.1.163","article-title":"Sensitization of Tumor Cells to NK","volume":"180","year":"2008","journal-title":"J. Immunol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"720","DOI":"10.4149\/neo_2018_171019N668","article-title":"Carfilzomib combined with ex vivo-expanded patient autologous natural killer cells for myeloma immunotherapy","volume":"65","author":"Chang","year":"2018","journal-title":"Neoplasma"},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Motais, B., Charv\u00e1tov\u00e1, S., Walek, Z., H\u00e1jek, R., and Bag\u00f3, J.R. (2023). NK92 expressing anti-BCMA CAR and secreted TRAIL for the treatment of multiple myeloma: Preliminary in vitro assessment. Cells, 12.","DOI":"10.20944\/preprints202308.1611.v1"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-024-01604-y","article-title":"Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia","volume":"17","author":"Sedloev","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12935-024-03424-z","article-title":"Enhancing cancer therapy: The integration of oncolytic virus therapy with diverse treatments","volume":"24","author":"Yan","year":"2024","journal-title":"Cancer Cell Int."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.omto.2023.04.008","article-title":"Opportunities and challenges of combining adoptive cellular therapy with oncolytic virotherapy","volume":"29","author":"Mamola","year":"2023","journal-title":"Mol. Ther.-Oncolytics"},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Chaurasiya, S., Woo, Y., Choong, K., Deshpande, S., and Fong, Y. (2023). Combining oncolytic viruses with immune cell therapy as treatments for cancer: OV, CAR T-cell, and NK combinations. NK Cells in Cancer Immunotherapy: Successes and Challenges, Elsevier.","DOI":"10.1016\/B978-0-12-822620-9.00006-9"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.1158\/1538-7445.AM2022-6225","article-title":"Developing a novel combination therapy using engineered chimeric antigen receptor natural killer cells targeting avsialidase with avsialidase-armed oncolytic vaccinia virus in solid tumor models","volume":"82","author":"Wang","year":"2022","journal-title":"Cancer Res."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"e002866","DOI":"10.1136\/jitc-2021-002866","article-title":"NK cells enhance CAR-T cell antitumor efficacy by enhancing immune\/tumor cells cluster formation and improving CAR-T cell fitness","volume":"9","author":"Bachiller","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1158\/1538-7445.AM2020-4235","article-title":"A combination of CAR-NK and CAR-T cells results in rapid and persistent anti-tumor efficacy while reducing CAR-T cell mediated cytokine release and T-cell proliferation","volume":"80","author":"Li","year":"2020","journal-title":"Am. Assoc. Cancer Res."},{"key":"ref_175","first-page":"166","article-title":"Tumor infiltrating cells in human cancer. On the possible role of CD16+ macrophages in antitumor cytotoxicity","volume":"67","author":"Kluin","year":"1992","journal-title":"Lab. Investig. J. Tech. Methods Pathol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-017-0430-2","article-title":"Tumor-associated macrophages: From basic research to clinical application","volume":"10","author":"Yang","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1900192","DOI":"10.1002\/adma.201900192","article-title":"Photothermal therapy promotes tumor infiltration and antitumor activity of CAR T cells","volume":"31","author":"Chen","year":"2019","journal-title":"Adv. Mater."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/s41551-021-00781-2","article-title":"Enhanced intratumoural activity of CAR T cells engineered to produce immunomodulators under photothermal control","volume":"5","author":"Miller","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Kong, J.C., Sa\u2019ad, M.A., Vijayan, H.M., Ravichandran, M., Balakrishnan, V., Tham, S.K., and Tye, G.J. (2024). Chimeric antigen receptor-natural killer cell therapy: Current advancements and strategies to overcome challenges. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1384039"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-019-0982-6","article-title":"Exosome-orchestrated hypoxic tumor microenvironment","volume":"18","author":"Meng","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"4598476","DOI":"10.1155\/2020\/4598476","article-title":"Hypoxia Impairs NK Cell Cytotoxicity through SHP-1-Mediated Attenuation of STAT3 and ERK Signaling Pathways","volume":"2020","author":"Teng","year":"2020","journal-title":"J. Immunol. Res."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"17450","DOI":"10.1073\/pnas.1304790110","article-title":"Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia","volume":"110","author":"Baginska","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1002\/eji.201343448","article-title":"Hypoxia downregulates the expression of activating receptors involved in NK-cell-mediated target cell killing without affecting ADCC","volume":"43","author":"Balsamo","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Lim, J., Lu, A., Li, Y., and Bronevetsky, Y. (2022). 398 Expansion of therapeutic NK cell line under hypoxic and hyperbaric culture conditions enhances anti-tumor potency. BMJ Spec. J.","DOI":"10.1136\/jitc-2022-SITC2022.0398"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1158\/1538-7445.AM2018-122","article-title":"Hypoxia-enhanced proliferation and effector function of NK cells","volume":"78","author":"Moon","year":"2018","journal-title":"Cancer Res."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"e000246","DOI":"10.1136\/jitc-2019-000246","article-title":"Overcoming hypoxia-induced functional suppression of NK cells","volume":"8","author":"Solocinski","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jcyt.2016.12.005","article-title":"Cord blood natural killer cells expressing a dominant negative TGF-\u03b2 receptor: Implications for adoptive immunotherapy for glioblastoma","volume":"19","author":"Yvon","year":"2017","journal-title":"Cytotherapy"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/leu.2015.327","article-title":"The TGF-\u03b2\/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia","volume":"30","author":"Rouce","year":"2016","journal-title":"Leukemia"},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Thangaraj, J.L., Coffey, M., and Kaufman, D.S. (2023). 311 Disruption of TGF-b signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells. BMJ Spec. J.","DOI":"10.1136\/jitc-2023-SITC2023.0311"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"e142116","DOI":"10.1172\/JCI142116","article-title":"Targeting the \u03b1v integrin\/TGF-\u03b2 axis improves natural killer cell function against glioblastoma stem cells","volume":"131","author":"Shaim","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"ra19","DOI":"10.1126\/scisignal.aad1884","article-title":"TGF-\u03b2 inhibits the activation and functions of NK cells by repressing the mTOR pathway","volume":"9","author":"Viel","year":"2016","journal-title":"Sci. Signal."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Otegbeye, F., Ojo, E., Moreton, S., Mackowski, N., Lee, D.A., De Lima, M., and Wald, D.N. (2018). Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0191358"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS273","article-title":"Trial in progress: Natural killer (NK) cells with TGF\u03b2 receptor I inhibitor vactosertib and IL-2 in patients with metastatic colorectal cancer or hematologic malignancies","volume":"41","author":"Selfridge","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Oh, M.-S., Seo, M., Yoon, S., and Jang, M. (2023). 292 Unleashing CAR-NK cells against solid tumors by disrupting TGF-\u03b2 signaling in the tumor microenvironment. BMJ Spec. J.","DOI":"10.1136\/jitc-2023-SITC2023.0292"},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"hun Shin, S., Lee, Y.E., Yoon, H.N., Yuk, C.M., An, J.Y., Seo, M., Yoon, S., Oh, M.S., Shin, S.C., and Kim, J.H. (2025). An innovative strategy harnessing self-activating CAR-NK cells to mitigate TGF-\u03b21-driven immune suppression. Biomaterials, 314.","DOI":"10.1016\/j.biomaterials.2024.122888"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00109-012-0988-7","article-title":"Transcriptional control of adenosine signaling by hypoxia-inducible transcription factors during ischemic or inflammatory disease","volume":"91","author":"Poth","year":"2013","journal-title":"J. Mol. Med."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0360-8","article-title":"Targeting adenosine for cancer immunotherapy","volume":"6","author":"Leone","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_198","doi-asserted-by":"crossref","unstructured":"Chambers, A.M., Wang, J., Lupo, K.B., Yu, H., Atallah Lanman, N.M., and Matosevic, S. (2018). Adenosinergic signaling alters natural killer cell functional responses. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02533"},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Nachef, M., Ali, A.K., Almutairi, S.M., and Lee, S.-H. (2021). Targeting SLC1A5 and SLC3A2\/SLC7A5 as a potential strategy to strengthen anti-tumor immunity in the tumor microenvironment. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.624324"},{"key":"ref_200","first-page":"2451","article-title":"Dual antigen\u2013targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia","volume":"140","author":"Cichocki","year":"2022","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1158\/1538-7445.AM2023-4077","article-title":"Dual-targeted CAR-NK cell therapy: Optimized CAR design to prevent antigen escape and elicit a deep and durable response in multiple myeloma","volume":"83","author":"Yang","year":"2023","journal-title":"Cancer Res."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s12967-024-04990-6","article-title":"CD19\/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia","volume":"22","author":"Yang","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"S440","DOI":"10.1016\/S2152-2650(22)01658-5","article-title":"CT-227 Dual CAR-Engineered NK92 Cells: An Off-the-Shelf Cell Therapy for Cancer","volume":"22","author":"Zuccolotto","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Eitler, J., Ben-Horin, I., Freudenberg, K., Ortiz-Montero, P., Loureiro, L.R., Rackwitz, W., K\u00fcnzel, S.R., H\u00f6lig, K., Feldmann, A., and Bachmann, M. (2024). 256 Dual targeting of PD-L1 and ErbB2 by CAR-NK cells enables specific elimination of solid tumor cells and overcomes immune escape via antigen loss. BMJ Spec. J.","DOI":"10.1136\/jitc-2024-SITC2024.0256"},{"key":"ref_205","doi-asserted-by":"crossref","unstructured":"Zhi, L., Zhang, Z., Gao, Q., Shang, C., He, W., Wang, Y., Guo, C., Niu, Z., and Zhu, W. (2025). CAR-NK cells with dual targeting of PD-L1 and MICA\/B in lung cancer tumor models. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-13821-w"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-022-02003-x","article-title":"KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape","volume":"28","author":"Li","year":"2022","journal-title":"Nat. Med."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2019-129319","article-title":"FT596: Translation of first-of-kind multi-antigen targeted off-the-shelf CAR-NK cell with engineered persistence for the treatment of B cell malignancies","volume":"134","author":"Goodridge","year":"2019","journal-title":"Blood"},{"key":"ref_208","doi-asserted-by":"crossref","unstructured":"Mitwasi, N., Feldmann, A., Arndt, C., Koristka, S., Berndt, N., Jureczek, J., Loureiro, L.R., Bergmann, R., M\u00e1th\u00e9, D., and Heged\u00fcs, N. (2020). \u201cUniCAR\u201d-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-59082-4"},{"key":"ref_209","doi-asserted-by":"crossref","unstructured":"Kang, H.Y., Lee, S.Y., Kim, H.M., Lee, S.U., Lee, H., Cho, M.Y., Oh, S.-C., Kim, S.-M., Park, H.S., and Han, E.H. (2023). A modifiable universal cotinine-chimeric antigen system of NK cells with multiple targets. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1089369"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1182\/bloodadvances.2020001510","article-title":"Inducible MyD88\/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells","volume":"4","author":"Wang","year":"2020","journal-title":"Blood Adv."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"101121","DOI":"10.1016\/j.gendis.2023.101121","article-title":"CRISPR, CAR-T, and NK: Current applications and future perspectives","volume":"11","author":"Khoshandam","year":"2024","journal-title":"Genes Dis."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood-2021-148649","article-title":"Engineering CD70-directed CAR-NK cells for the treatment of hematological and solid malignancies","volume":"138","author":"Choi","year":"2021","journal-title":"Blood"},{"key":"ref_213","first-page":"A123","article-title":"CISH gene-knockout anti-CD70-CAR NK cells demonstrate potent anti-tumor activity against solid tumor cell lines and provide partial resistance to tumor microenvironment inhibition","volume":"9","author":"Guo","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.ymthe.2025.01.024","article-title":"Virus-free CRISPR knockin of a chimeric antigen receptor into KLRC1 generates potent GD2-specific natural killer cells","volume":"33","author":"Shankar","year":"2024","journal-title":"Mol. Ther."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1677\/erc.1.00766","article-title":"Identification and validation of cell surface antigens for antibody targeting in oncology","volume":"11","author":"Carter","year":"2004","journal-title":"Endocr.-Relat. Cancer"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41597-024-03002-y","article-title":"A single cell RNAseq benchmark experiment embedding \u201ccontrolled\u201d cancer heterogeneity","volume":"11","author":"Arigoni","year":"2024","journal-title":"Sci. Data"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3109\/07357909009017573","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast cancer","volume":"8","author":"Slamon","year":"1990","journal-title":"Cancer Investig."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/mt.2014.219","article-title":"Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2\/HER2-specific chimeric antigen receptor","volume":"23","author":"Sahm","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"17481","DOI":"10.1073\/pnas.0804788105","article-title":"Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas","volume":"105","author":"Kruschinski","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"102619","DOI":"10.1016\/j.isci.2021.102619","article-title":"Expanded human NK cells armed with CAR uncouple potent anti-tumor activity from off-tumor toxicity against solid tumors","volume":"24","author":"Portillo","year":"2021","journal-title":"Iscience"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"e002980","DOI":"10.1136\/jitc-2021-002980","article-title":"Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity","volume":"9","author":"Zhang","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"142.102","DOI":"10.4049\/jimmunol.210.Supp.142.02","article-title":"Targeting CD70 using CAR NK cells to enhance NK cells cytolytic effect against osteosarcoma","volume":"210","author":"Rav","year":"2023","journal-title":"J. Immunol."},{"key":"ref_223","doi-asserted-by":"crossref","unstructured":"Montagner, I.M., Penna, A., Fracasso, G., Carpanese, D., Dalla Piet\u00e0, A., Barbieri, V., Zuccolotto, G., and Rosato, A. (2020). Anti-PSMA CAR-engineered NK-92 cells: An off-the-shelf cell therapy for prostate cancer. Cells, 9.","DOI":"10.20944\/preprints202005.0259.v1"},{"key":"ref_224","doi-asserted-by":"crossref","unstructured":"Lin, X., Guan, T., Li, Y., Lin, Y., Huang, G., Lin, Y., Sun, P., Li, C., Gu, J., and Zeng, H. (2024). Efficacy of MUC1-targeted CAR-NK cells against human tongue squamous cell carcinoma. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1337557"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bbrc.2020.01.053","article-title":"Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer","volume":"524","author":"Cao","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"4864","DOI":"10.1111\/febs.16880","article-title":"CD24 targeting with NK-CAR immunotherapy in testis, prostate, renal and (luminal-type) bladder cancer and identification of direct CD24 interaction partners","volume":"290","author":"Thomas","year":"2023","journal-title":"FEBS J."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"e70140","DOI":"10.1002\/ctm2.70140","article-title":"Enhancement of anti-sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2-targeted CAR","volume":"15","author":"Lam","year":"2025","journal-title":"Clin. Transl. Med."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00262-024-03923-y","article-title":"Therapeutic potential of anti-ErbB3 chimeric antigen receptor natural killer cells against breast cancer","volume":"74","author":"Lee","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","article-title":"Co-opting signalling molecules enables logic-gated control of CAR T cells","volume":"615","author":"Tousley","year":"2023","journal-title":"Nature"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","article-title":"Engineering T cells with customized therapeutic response programs using synthetic notch receptors","volume":"167","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.3390\/cimb46040183","article-title":"Augmenting the antitumor efficacy of natural killer cells via synNotch receptor engineering for targeted IL-12 secretion","volume":"46","author":"Ahmadnia","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"25151355241305856","DOI":"10.1177\/25151355241305856","article-title":"Artificial intelligence for chimeric antigen receptor-based therapies: A comprehensive review of current applications and future perspectives","volume":"12","author":"Shahzadi","year":"2024","journal-title":"Ther. Adv. Vaccines Immunother."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"176","DOI":"10.5603\/AHP.a2022.0019","article-title":"Artificial intelligence and chimeric antigen receptor T-cell therapy","volume":"53","author":"Gil","year":"2022","journal-title":"Acta Haematol. Pol."},{"key":"ref_234","doi-asserted-by":"crossref","unstructured":"Wang, Q., Yuan, X., Liu, C., Huang, Y., Li, L., and Zhu, Y. (2025). Peptide-based CAR-NK cells: A novel strategy for the treatment of solid tumors. Biochem. Pharmacol., 232.","DOI":"10.1016\/j.bcp.2025.116741"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/13\/6290\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:01:24Z","timestamp":1760032884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/13\/6290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,29]]},"references-count":234,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["ijms26136290"],"URL":"https:\/\/doi.org\/10.3390\/ijms26136290","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,29]]}}}